viewC4X Discovery Holdings PLC

C4X teams up with PhoreMost to look for potential Parkinson’s treatments

By combining their drug discovery and validation platforms, C4X and PhoreMost hope to find drug targets that can potentially treat Parkinson’s sufferers

old man
There is potential for the pair to look for drugs for other as-yet untreatable diseases

C4X Discovery Holdings plc (LON:C4XD) has teamed up with fellow UK-based biopharma, PhoreMost, to look for treatments for Parkinson’s Disease and other ‘undruggable’ diseases.

The pair will take potentially useful compounds already identified by C4X’s Taxonomy 3 platform and run them through PhoreMost’s SITESEEKER screening platform.

That data can then be exploited by C4X’s Conformetrix drug discovery platform to help produce “commercially attractive small molecule drugs”.

READ: C4X sees significant interest in drug programme

While the initial focus is on Parkinson’s, C4X and PhoreMost believe the complementary nature of the technology platforms means there is potential to extend the collaboration to additional indications in the future.

“As part of our strategy to become the world's most productive drug discovery company, we continually assess cutting edge technologies that add to our current capabilities in target identification and drug design,” said C4X chief executive Clive Dix.

“PhoreMost has one such technology with the potential to both validate targets and provide chemistry starting points for our molecular design platforms.

“This partnership complements C4XD's existing target validation collaborations and enables us to accelerate our portfolio growth whilst decreasing the timelines in drug discovery.”

PhoreMost CEO, Chris Torrance, added: “We are thrilled to be joining forces with C4XD within this neurodegeneration collaboration, a therapeutic area that has a pressing need for new and better targets.”

C4X shares were up 4.6% to 52.8p in early deals on Tuesday.

Quick facts: C4X Discovery Holdings PLC

Price: 12.5 GBX

Market: AIM
Market Cap: £13.55 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of C4X Discovery Holdings PLC named herein, including the promotion by the Company of C4X Discovery Holdings PLC in any Content on the Site, the...



Full interview: C4X Discovery fully cashed up and sees big potential for its...

C4X Discovery Holdings plc's (LON:C4XD) Clive Dix speaks to Proactive London's Andrew Scott following the news they've raised around £6.6mln to strengthen its balance sheet amid ongoing licensing discussions for its early-stage drug candidates. While expressing regret for the level at which...

on 25/10/19

2 min read